Therapeutic Effectiveness of Minimal Doses of Rituximab in a Patient with Rheumatoid Arthritis

No abstract is available for this paper.

• Publication year

  2011

• Venue

  International Journal of Immunopathology and Pharmacology

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/039463201102400135PMID 21496414
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)

  2016cited by this paper
• Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab).

  2011cited by this paper
• Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))

  2010cited by this paper
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.

  2006cited by this paper

• Patients' and rheumatologists' perceptions on dose reduction of rituximab in rheumatoid arthritis.

  2024cites this paper
• Long-term clinical and radiological effectiveness and safety of ultralow doses of rituximab in rheumatoid arthritis: observational extension of the REDO trial

  2024cites this paper
• [Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report].

  2024cites this paper
• Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on low dose rituximab.

  2022cites this paper
• Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis /dermatomyositis associated ILD.

  2020cites this paper
• Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.

  2019cites this paper
• How low can we go for continued dosing of rituximab in rheumatoid arthritis?

  2019cites this paper
• Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial

  2017cites this paper
• bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search

  2017cites this paper
• Prompt efficacy of very low‐dose rituximab on monoclonal B lymphocytosis in a rheumatoid arthritis patient

  2013cites this paper
• Interleukin-9 and mast cells.

  2012cites this paper